Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR :: ABL1 digital PCR in chronic myeloid leukemia patients
European Journal of Haematology · 2024-11 · 113 (5) · 606-613
DOI: 10.1111/ejh.14271 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 12.07.2024. Verfasst von Camille Kockerols und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Polymerase Chain Reaction, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth of molecular response measured by BCR::ABL1 digital PCR (dPCR). The aim of this study was to validate a previously described prediction cutoff of 0.0023% IS and to assess the value of dPCR for treatment‐free remission (TFR) prediction in relation to other clinical parameters. A droplet‐based dPCR assay assessed BCR::ABL1 % IS prior to TKI discontinuation. The primary endpoint was molecular recurrence (MolR) by 36 months. A total of 186 patients from Canada, Germany, and the Netherlands were included. In patients with a first TKI discontinuation attempt ( n = 163), a BCR::ABL1 dPCR < and ≥0.0023% IS had a MolR probability of 33% and 70%, respectively. Patients treated less than 6 years with a BCR::ABL1 dPCR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
- Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
- Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
- Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
- III. Med Clinic, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
- Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
ORCID-Profile: Dennis Kim, Peter E Westerweel
Zitieren
APA
Kockerols, C., Valk, P. J. M., Janssen, J. J. W. M., Hogenbirk, P., Cornelissen, J. J., Saussele, S., Spiess, B., Perusini, M. A., Kim, D., & Westerweel, P. E. (2024). Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR :: ABL1 digital PCR in chronic myeloid leukemia patients. European Journal of Haematology, 113(5), 606-613. https://doi.org/10.1111/ejh.14271
Vancouver
Kockerols C, Valk PJM, Janssen JJWM, Hogenbirk P, Cornelissen JJ, Saussele S, et al. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR :: ABL1 digital PCR in chronic myeloid leukemia patients. European Journal of Haematology. 2024;113(5):606-613. doi:10.1111/ejh.14271
BibTeX
@article{Kockerols2024,
author = {Kockerols, Camille and Valk, Peter J M and Janssen, Jeroen J W M and Hogenbirk, Pauline and Cornelissen, Jan J and Saussele, Susanne and Spiess, Birgit and Perusini, Maria Agustina and Kim, Dennis and Westerweel, Peter E},
title = {Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR :: ABL1 digital PCR in chronic myeloid leukemia patients},
journal = {European Journal of Haematology},
year = {2024},
volume = {113},
number = {5},
pages = {606--613},
doi = {10.1111/ejh.14271}
}
EUVIMED